512 — Grand Pharmaceutical Balance Sheet
0.000.00%
- HK$20.28bn
- HK$21.99bn
- HK$11.64bn
- 62
- 70
- 90
- 88
Annual balance sheet for Grand Pharmaceutical, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,357 | 2,866 | 2,483 | 2,112 | 2,779 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,716 | 2,149 | 2,207 | 2,686 | 3,285 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,319 | 6,779 | 6,887 | 7,016 | 8,026 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,410 | 3,802 | 3,942 | 3,986 | 4,266 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 16,984 | 21,057 | 22,371 | 22,515 | 24,991 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,303 | 5,566 | 6,455 | 5,731 | 6,573 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 5,745 | 7,664 | 8,231 | 7,358 | 8,518 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 11,240 | 13,393 | 14,140 | 15,158 | 16,473 |
Total Liabilities & Shareholders' Equity | 16,984 | 21,057 | 22,371 | 22,515 | 24,991 |
Total Common Shares Outstanding |